Beijing Cancer Hospital ( Site 0601)

Beijing, Beijing Municipality 100036

0 studies enrolling now · 1 studies all time

What they study most

Malignant Melanoma

Studies at this site

• Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) — Completed